Subscribe to Search results

The CSM(B) stated that "the perceived level of risk" did not justify a "serious consideration" of withdrawing USA products from the UK Market. In addition it was not feasible on the grounds of supply.

Published on:

Dr Walford said she did not know the replacement of concentrates with cryoprecipitate was not feasible.

Published on:

Dr Lane produced a report on Acquired Immune Deficiency Syndrome for the CBLA on 22 April 1983.

Published on:

Sir Joseph Smith stated in 1983 that he was sure UK self-sufficiency was expected soon.

Published on:

Cutter learned that the French were offered heat-treated product by Hyland and Behringwerke earlier in 1983. As a result the French had stopped all imports "until they can evaluate the information and offers they have received insofar as they relate to the hepatitis and AIDS questions."

Published on:

Professor Christopher Bartlett in his written statement to the Archer Inquiry, referring to Dr Galbraith's letter and paper of the 9 May 1983, explained that Dr Galbraith had sought his opinion on the final drafts and that he fully concurred with the conclusions and advice he had expressed.

Published on:

Professor Stephen Palmer was appointed as PHLS CDSC's first medical consultant epidemiologist for Wales.

Published on:

Professor Stephen Palmer noted that Dr Galbraith was sick and not present for the CDSC in mid 1983.

Published on:

Dr Galbraith's colleague stated that he was off work for six weeks due to severe arthritis.

Published on:

The Council of Europe recommended the governments of member states to take all necessary steps and measures in relation to AIDS,mainly to avoid use of coagulation factor products prepared from large plasma pools.

Published on:

Lord Glenarthur was not aware of the CSM(B)'s 13th July meeting regarding AIDs.

Published on:

Lord Kenneth Clarke was not aware of the CSM(B)'s existence and was surprised Lord Simon Glenarthur was unaware of the CSM(B) meetings and deliberations.

Published on:

Professor Richard Tedder stated in his statement to the Inquiry ""Personally, I would have recalled, prevented or very strictly controlled the use of imported commercial blood products, especially those from the USA, which were known to have a significant risk over and above the expected. If the same was to occur with a British product, then clearly recall would be appropriate. At the Middlesex we would only have used such products if it was the only option to avoid serious harm to a patient".

Published on:

Professor Tedder emphasized in his oral evidence that the use of prisoners for donated blood, particularly in the US, meant that the producer of the product would not know their donor.

Published on:

In a minute from Dr Smith to Dr Lane, it was suggested that importation of US concentrate should cease on the ground of the risk of hepatitis alone.

Published on:

At a meeting of the Reference Centre Directors it was agreed that for young children, and those who were newly diagnosed with haemophilia, cryoprecipitate was to be used. Next preference was to be given to NHS factor concentrate.

Published on:

At a meeting of the CSM(B), it was stated that clotting concentrates were "life-saving" for haemophiliacs and the risk of AIDs was considered small. It was concluded that withdrawal of clotting factor concentrates from the market was not feasible on the grounds of supply.

Published on:

A hierarchy of safety used by the UKHCDO was implemented meaning that for those newly diagnosed with haemophilia, cryoprecipitate was used. Preference was then given to NHS Factor concentrate with US Factor concentrate given as a last resort.

Published on:

Dr Biggs stated that "Cryoprecipitate is a simple concentrate made from plasma at all Regional Transfusion Centres. Cryoprecipitate is much superior to plasma for the treatment of haemophilia A patients but the material is very variable from one sample to another and the potency cannot be known before it is used. For each dose the assumption must be made that the material is of low potency thus there is a tendency to use more material for each patient than is probably needed."

Published on:

Donations were tested for HTLV-3 at Oxford from this date with a temporal scope of six (rather than the national standard of five) years.

Published on: